Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Intensity Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 14 | 17 | +3 |
| Shares | 180.3K | 1.17M | +988.4K (+548.3%) |
| Value | $1.06M | $4.79M | +$3.73M (+352.0%) |
New holders (4)
Institutions that held Intensity Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| KMT Wealth Management, LLC | 496,493 | $2.04M | 1.72% |
| FNY Investment Advisers, LLC | 22,000 | $90.0K | 0.03% |
| Barclays PLC | 42 | $172 | 0.00% |
| Caitong International Asset Management Co., Ltd | 6 | $25 | 0.00% |
Sold out (1)
Institutions that held Intensity Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Wells Fargo & Company | 200 | $1.18K |